New coronavirus infection and liver lesions

Abstract

BACKGROUND: According to published research outcomes, liver dysfunction is one of the predictors of adverse outcome COVID-19.

AIM: To study the frequency and severity of liver damage in COVID-19 and suggest therapeutic and prevention approaches to liver damage.

MATERIALS AND METHODS: The study included 171 patients with SARS-CoV-2 pneumonia at the age of 21–94 (mean age 59.85 ± 14.96). Clinical and biochemical blood tests, coagulogram, blood ammonia test, number linkage test, multislice computed tomography of the chest, and ¹³C-metacetin breath test. Patients were divided into two groups depending on the volume of lung injury. Statistical processing of the results was performed with the software SPSS 26.

RESULTS: The most frequent symptoms were manifestations of intoxication syndrome, respiratory failure, the severity of which correlated with the volume of lung tissue damage according to multislice computed tomography of the chest. In both groups, the activity of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltranspeptidase, and alkaline phosphate increased. However, significant distinctions in the groups were revealed only for gamma-glutamyltranspeptidase and alkaline phosphate levels. The level of C-reactive protein in both groups directly correlated with the level of cytolysis and cholestasis, indicating a significant role of the liver in pathological processes in COVID-19. Conclusion: Hyperammonemia and decreased liver functional reserve of various severity were observed in all patients.

CONCLUSIONS: The findings indicate the diagnostic value of the studied parameters for the evaluation of liver damage, as well as the applications of prevention and treatment measures for liver lesions in patients with COVID-19.

Keywords

COVID-19 / liver / 13C-methacetyl breath test / cytolysis / encephalopathy / ammonia

References

[1] WHO COVID-19 Dashboard [Internet]. World Health Organization. 2020. Available from: https://covid19.who.int/. Accessed: 25.05.2023.

[2] WHO COVID-19 Dashboard [Электронный ресурс] // World Health Organization. 2020. Режим доступа: https://covid19.who.int/. Дата обращения: 25.05.20223.

[3] Simmonds P. Rampant C → U hypermutation in the genomes of SARS-CoV-2 and other Coronaviruses: causes and consequences for their short-and long-term evolutionary trajectories. mSphere. 2020;5(3):e00408–20. DOI: 10.1128/mSphere.00408-20

[4] Simmonds P. Rampant C → U hypermutation in the genomes of SARS-CoV-2 and other Coronaviruses: causes and consequences for their short-and long-term evolutionary trajectories // mSphere. 2020. Vol. 5, No. 3. P. e00408–20. DOI: 10.1128/mSphere.00408-20

[5] Dawood DRM, Salum GM, El-Meguid MA. The impact of COVID-19 on liver injury. Am J Med Sci. 2022;363(2):94–103. DOI: 10.1016/j.amjms.2021.11.001

[6] Dawood D.R.M., Salum G.M., El-Meguid M.A. The impact of COVID-19 on liver injury // Am. J. Med. Sci. 2022. Vol. 363, No. 2. P. 94–103. DOI: 10.1016/j.amjms.2021.11.001

[7] Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the liver: Lessons learnt from the EAST and the WEST, a year later. J Viral Hepat. 2022;29(1):4–20. DOI: 10.1111/jvh.13590

[8] Ekpanyapong S., Bunchorntavakul C., Reddy K.R. COVID-19 and the liver: Lessons learnt from the EAST and the WEST, a year later // J. Viral. Hepat. 2022. Vol. 29, No. 1. P. 4–20. DOI: 10.1111/jvh.13590

[9] Li P, Liu Y, Cheng Z, et al. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother. 2022;154:113568. DOI: 10.1016/j.biopha.2022.113568

[10] Li P., Liu Y., Cheng Z. et al. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management // Biomed. Pharmacother. 2022. Vol. 154. P. 113568. DOI: 10.1016/j.biopha.2022.113568

[11] Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases. 2022;10(4):1140–1163. DOI: 10.12998/wjcc.v10.i4.1140

[12] Ozkurt Z., Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations // World J. Clin. Cases. 2022. Vol. 10, No. 4. P. 1140–1163. DOI: 10.12998/wjcc.v10.i4.1140

[13] D’Ardes D, Boccatonda A, Cocco G, et al. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship. World J Gastroenterol. 2022;28(11):1102–1112. DOI: 10.3748/wjg.v28.i11.1102

[14] D’Ardes D., Boccatonda A., Cocco G. et al. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship // World J. Gastroenterol. 2022. Vol. 28, No. 11. P. 1102–1112. DOI: 10.3748/wjg.v28.i11.1102

[15] Mohammed SA, Eid KM, Anyiam FE, et al. Liver injury with COVID-19: laboratory and histopathological outcome-systematic review and meta-analysis. Egypt Liver J. 2022;12(1):9. DOI: 10.1186/s43066-022-00171-6

[16] Mohammed S.A., Eid K.M., Anyiam F.E. et al. Liver injury with COVID-19: laboratory and histopathological outcome-systematic review and meta-analysis // Egypt Liver J. 2022. Vol. 12, No. 1. P. 9. DOI: 10.1186/s43066-022-00171-6

[17] Kariyawasam JC, Jayarajah U, Abeysuriya V, et al. Involvement of the liver in COVID-19: a systematic review. Am J Trop Med Hyg. 2022;106(4):1026–1041. DOI: 10.4269/ajtmh.21-1240

[18] Kariyawasam J.C., Jayarajah U., Abeysuriya V. et al. Involvement of the liver in COVID-19: a systematic review // Am. J. Trop. Med. Hyg. 2022. Vol. 106, No. 4. P. 1026–1041. DOI: 10.4269/ajtmh.21-1240

[19] Vremennye metodicheskie rekomendatsii “Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiya 17 (09.12.2022)”. (In Russ.)

[20] Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (09.12.2022).»

[21] Medvedev YuV, BakuLin IG, Nemtsova EG, et al. Innovative use of 13C-methacetin breathing test to assess the rate of hepatic fibrosis. Doctor.Ru. 2019;8(163):6–12. (In Russ.) DOI: 10.31550/1727-2378-2019-163-8-6-12

[22] Медведев Ю.В., Бакулин И.Г., Немцова Е.Г. и др. Инновации в применении 13С-метацетинового дыхательного теста для оценки степени фиброза печени // Доктор.Ру. 2019. Т. 8, № 163. С. 6–12. DOI: 10.31550/1727-2378-2019-163-8-6-12

[23] Lazebnik LB, Golovanova EV, Alekseenko SA, et al. Russian Consensus “Hyperammonemia in Adults” (Version 2021). Experimental and Clinical Gastroenterology. 2021;(3):97–118. (In Russ.) DOI: 10.31146/1682-8658-ecg-187-3-97-118

[24] Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. и др. Российский консенсус «Гипераммониемии у взрослых» (Версия 2021) // Экспериментальная и клиническая гастроэнтерология. 2021. № 3. С. 97–118. DOI: 10.31146/1682-8658-ecg-187-3-97-118

[25] Sayganov SA, Mazurov VI, Bakulin IG, et al. Current, effectiveness of therapy and outcomes of new coronavirus infection: preliminary analysis. Herald of North-Western State Medical University named after I.I. Mechnikov. 2020;12(2):27–38. (In Russ.) DOI: 10.17816/mechnikov34932

[26] Сайганов С.А., Мазуров В.И., Бакулин И.Г. и др. Клиническое течение, эффективность терапии и исходы новой коронавирусной инфекции: предварительный анализ // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2020. Т. 12, № 2. С. 27–38. DOI: 10.17816/mechnikov34932

[27] Drapkina OM, Maev IV, Bakulin IG, et al. Provisional guidelines: “diseases of the digestive organs in conditions of a pandemic new coronavirus infection (COVID-19)”. Version 2. Profilakticheskaya Meditsina. 2021;24(5–2):4–41. (In Russ.) DOI: 10.17116/profmed2021240524

[28] Драпкина О.М., Маев И.В., Бакулин И.Г. и др. Временные методические рекомендации: «Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19)». Версия 2 // Профилактическая медицина. 2021. Т. 24, № 5–2. С. 4–41. DOI: 10.17116/profmed2021240524

[29] Ianushevich OO, Maev IV, Krikheli NI, et al. Prevalence and prognostic value of gastroenterological manifestations of COVID-19: data from the Russian University Clinic. Terapevticheskii arkhiv. 2021;93(8):853–861. (In Russ.) DOI: 10.26442/00403660.2021.08.200977

[30] Янушевич О.О., Маев И.В., Крихели Н.И. и др. Распространенность и прогностическое значение гастроэнтерологических проявлений COVID-19: данные Российской университетской клиники // Терапевтический архив. 2021. Т. 93, № 8. С. 853–861. DOI: 10.26442/00403660.2021.08.200977

RIGHTS & PERMISSIONS

Eco-Vector